Navigation Links
Edoxaban Significantly Reduces Risk of Venous Thromboembolism by Half Compared to Enoxaparin in Japanese and Taiwanese Patients Following Knee or Hip Arthroplasty Surgery
Date:12/12/2011

folio of marketed pharmaceuticals for hypertension, hyperlipidemia, and bacterial infections, the Group is engaged in the development of treatments for thrombotic disorders and focused on the discovery of novel oncology and cardiovascular-metabolic therapies. Furthermore, the Daiichi Sankyo Group has created a "Hybrid Business Model," which will respond to market and customer diversity and optimize growth opportunities across the value chain. For more information, please visit www.daiichisankyo.com

Forward-Looking Statements
This press release contains forward-looking statements and information about future developments in the sector, and the legal and business conditions of DAIICHI SANKYO, Co. Ltd, DAIICHI SANKYO, Inc., and DAIICHI SANKYO EUROPE GmbH. Such forward-looking statements are uncertain and are subject at all times to the risks of change, particularly to the usual risks faced by a global pharmaceutical company, including the impact of the prices for products and raw materials, medication safety, changes in exchange rates, government regulations, employee relations, taxes, political instability and terrorism as well as the results of independent demands and governmental inquiries that affect the affairs of the company. All forward-looking statements contained in this release hold true as of the date of publication. They do not represent any guarantee of future performance. Actual events and developments could differ materially from the forward-looking statements that are explicitly expressed or implied in these statements. DAIICHI SANKYO, Co. Ltd, DAIICHI SANKYO, Inc., and DAIICHI SANKYO EUROPE GmbH assume no responsibility for the updating of such forward-looking statements about future developments of the sector, legal and business conditions and the company.

[i] T. Fuji et al., Edoxaban versus enoxaparin for thromboprophylaxis after total knee replacement: T
'/>"/>

SOURCE Daiichi Sankyo Company, Limited
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Analysis of Edoxaban Phase II Data Provides Insight Into Reduced Bleeding Events Seen in Once-Daily Dosing
2. Daiichi Sankyo Receives First Market Approval in Japan for LIXIANA® (edoxaban), a Direct Oral Factor Xa Inhibitor, for the Prevention of Venous Thromboembolism after Major Orthopedic Surgery
3. Daiichi Sankyo Launches LIXIANA® (edoxaban), a Direct Oral Factor Xa Inhibitor, in Japan for the Prevention of Venous Thromboembolism after Major Orthopedic Surgery
4. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
5. DEFLUX(R) Significantly Reduces Urinary Tract Infections in Children With Vesicoureteral Reflux
6. Vidaza Significantly Extends Overall Survival by 74% in Phase 3 Trial in Myelodysplastic Syndromes (MDS)
7. Nexavar Significantly Improved Overall Survival in Phase 3 Asia-Pacific Liver Cancer Trial
8. Study Shows Vasopressin Receptor Antagonist VAPRISOL(R) (Conivaptan Hydrochloride Injection) Significantly Increased Serum Sodium Concentration in Patients with Euvolemic & Hypervolemic Hyponatremia
9. New Data Reveal Topical Divigel(R) (estradiol gel) 0.1% Significantly Reduces Frequency and Severity of Hot Flashes
10. Promising Phase 3 Trial Results Show Novel Biologic Therapy Ustekinumab (CNTO 1275) Significantly Improved Psoriasis
11. INVEGA(TM) Significantly Reduced Symptoms of Schizophrenia Compared to SEROQUEL(R) in Acutely Ill, Hospitalized Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... , Aug. 29, 2014 Research ... "China Orthopedic Instrument Industry Report, 2014-2017" report ... aging population and rising proportion of reimbursement for medical ... effectively released, with its scale presenting a CAGR of ... products are three product segments of orthopedic instruments in ...
(Date:8/29/2014)... 2014 Research and Markets has ... Trend Forecast of Pharmaceutical Equipment Market in China, 2014-2018" ... and Development Trend Forecast of Pharmaceutical Equipment Market in ... China,s pharmaceutical equipment industry in the ... landscape, and business performance of domestic major enterprises, as ...
(Date:8/29/2014)... 29, 2014  Unilife Corporation ("Unilife" or "Company") (NASDAQ: ... it intends to release its financial results for the ... 2014 after market trading ends on Tuesday, September 9, ... call for 4:30 p.m. U.S. EDT on Tuesday, September ... to review the Company,s financial results, commercial partnerships, and ...
Breaking Medicine Technology:China Orthopedic Instrument Industry Report, 2014-2017 2Research and Development Trend Forecast of Pharmaceutical Equipment Market in China, 2014-2018 2Unilife Corporation to Announce Financial Results for Fiscal Year 2014 Fourth Quarter and Year End on Tuesday, September 9, 2014 2
... President Barack Obama was voted the most powerful person ... nation,s leading weekly healthcare business news magazine. It,s the second ... 100 Most Powerful People in Healthcare. "The passage ... spot for Obama," said Modern Healthcare Editor David ...
... Chilcott Completes Amendment to Existing Senior Secured Credit Facilities and Closes Senior... -- ARDEE, Ireland, Aug. ... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... function(data) { var s = ,; var first_result; // Results are keyed by longUrl, so we ...
Cached Medicine Technology:Obama Named the Most Powerful Person in Healthcare for Second Consecutive Year 2Warner Chilcott Completes Amendment to Existing Senior Secured Credit Facilities and Closes Senior Notes Offering; Company Declares Special Cash Dividend of $8.50 Per Share and Updates Full-Year 2010 Financial Guidance 2Warner Chilcott Completes Amendment to Existing Senior Secured Credit Facilities and Closes Senior Notes Offering; Company Declares Special Cash Dividend of $8.50 Per Share and Updates Full-Year 2010 Financial Guidance 3Warner Chilcott Completes Amendment to Existing Senior Secured Credit Facilities and Closes Senior Notes Offering; Company Declares Special Cash Dividend of $8.50 Per Share and Updates Full-Year 2010 Financial Guidance 4Warner Chilcott Completes Amendment to Existing Senior Secured Credit Facilities and Closes Senior Notes Offering; Company Declares Special Cash Dividend of $8.50 Per Share and Updates Full-Year 2010 Financial Guidance 5Warner Chilcott Completes Amendment to Existing Senior Secured Credit Facilities and Closes Senior Notes Offering; Company Declares Special Cash Dividend of $8.50 Per Share and Updates Full-Year 2010 Financial Guidance 6Warner Chilcott Completes Amendment to Existing Senior Secured Credit Facilities and Closes Senior Notes Offering; Company Declares Special Cash Dividend of $8.50 Per Share and Updates Full-Year 2010 Financial Guidance 7Warner Chilcott Completes Amendment to Existing Senior Secured Credit Facilities and Closes Senior Notes Offering; Company Declares Special Cash Dividend of $8.50 Per Share and Updates Full-Year 2010 Financial Guidance 8Warner Chilcott Completes Amendment to Existing Senior Secured Credit Facilities and Closes Senior Notes Offering; Company Declares Special Cash Dividend of $8.50 Per Share and Updates Full-Year 2010 Financial Guidance 9Warner Chilcott Completes Amendment to Existing Senior Secured Credit Facilities and Closes Senior Notes Offering; Company Declares Special Cash Dividend of $8.50 Per Share and Updates Full-Year 2010 Financial Guidance 10Warner Chilcott Completes Amendment to Existing Senior Secured Credit Facilities and Closes Senior Notes Offering; Company Declares Special Cash Dividend of $8.50 Per Share and Updates Full-Year 2010 Financial Guidance 11
(Date:8/30/2014)... (PRWEB) August 30, 2014 Hundreds of ... claims continue to move forward in U.S. courts, Bernstein ... AstraZeneca PLC on July 31, 2014, Byetta and Bydureon ... 409 product liability claims that allege the drugs caused ... that many of these claims are pending in a ...
(Date:8/30/2014)... Continuing to meet the skin health ... the addition of a new doctor and office in ... leading-edge skin care in Grand Rapids since 1980 is ... a doctor, my passion is making sure my patients ... Dermatology, I’m better able to focus on my patients ...
(Date:8/30/2014)... CO (PRWEB) August 30, 2014 In today’s ... increasingly difficult to get. Snoring and sleep apnea (a medical ... rob people and their bed partners of the rest they ... 45% of the population snores and 20 million people in ... 10% have been diagnosed and treated; and of those treated, ...
(Date:8/30/2014)... PA (PRWEB) August 30, 2014 "My ... result of a car accident," said one of two ... muscle strain in her shoulder and neck area. She ... invented reduced pain and pressure, assisting in comfort and ... the patent-pending PILLOW CRADLE to support the head, neck ...
(Date:8/30/2014)... August 30, 2014 Market Research ... 2009-2019 is a professional and in-depth market survey ... report firstly reviews the basic information of Lab ... The report then explores global and China’s top ... capacity, production value, and market share etc. , ...
Breaking Medicine News(10 mins):Health News:Byetta Lawsuits Move Forward, as Bernstein Liebhard LLP Notes Settlements in More than 80 Cases 2Health News:Byetta Lawsuits Move Forward, as Bernstein Liebhard LLP Notes Settlements in More than 80 Cases 3Health News:Expanding Care at the Forefront of Dermatology 2Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3Health News:Lab Oven Industry for Global and Chinese Market Forecasts to 2019 in New Research Report Available at ReportsnReports.com 2Health News:Lab Oven Industry for Global and Chinese Market Forecasts to 2019 in New Research Report Available at ReportsnReports.com 3Health News:Lab Oven Industry for Global and Chinese Market Forecasts to 2019 in New Research Report Available at ReportsnReports.com 4
... worst nightmare, a newborn baby going under the knife to ... the real work begins for parents. University of Alberta nursing ... brink as a former pediatric cardiology nurse; she wanted to ... not 100 per cent convinced that health-care professionals get what ...
... 26 The Providence Service,Corporation (Nasdaq: PRSC ) ... financial advisor. , In ... strategic,options relating to, among other things, delevering its debt, growing ... UBS,Investment Bank has been retained in connection with selling certain,non-strategic ...
... by phthalates in these products, experts say , , WEDNESDAY, ... common hairspray chemical while at work may be more ... urinary opening, a new report says. , Many ... products contain chemicals called phthalates, such as diethyl phthalate ...
... whose eyes are misaligned and point outward are ... by early adulthood, according to findings of a ... Pediatrics ( http://pediatrics.aappublications.org/cgi/content/full/122/5/1033 ), the official journal ... retrospective study examined the medical records of 407 ...
... and less time-consuming than in-person visits, study finds , , ... be as effective as face-to-face counseling in helping people ... Florida study included 234 obese women, ages 50 to ... All the women completed a six-month weight-loss program and ...
... practitioners from across the world are to share skills ... in South Africa, organised by the Wellcome Trust. , ... empower" will take place from 2-5 December at ... It will bring together practitioners working in the fields ...
Cached Medicine News:Health News:Parents are the unsung heroes 2Health News:Providence Service Corporation Retains UBS Investment Bank as its Financial Advisor in Connection With the Sale of Certain Non-Strategic Assets 2Health News:Over-the-Phone Weight Loss Counseling Works 2Health News:International workshop aims to boost public engagement work in developing countries 2Health News:International workshop aims to boost public engagement work in developing countries 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: